Luc Dochez, Pharm.D.
Dr. Dochez is a managing partner at DROIA Genetic Diseases and a partner at DROIA Oncology Ventures. He is also a co-founder of various biotech companies including Montis Biosciences, Pharvaris and Vico Therapeutics. Prior to joining DROIA, Dr. Dochez was chief executive officer of Tusk Therapeutics from May 2015 until its acquisition by Roche in September 2018. He joined Tusk from Prosensa Holding N.V., where he served as chief business officer and senior vice president of business development for seven years until its acquisition by BioMarin Pharmaceutical Inc. He has held multiple leadership roles in business development for TiGenix and Methexiz, and has also served as a consultant for Arthur D. Little. He currently serves on the board of directors for Erytech, Vico Therapeutics and Montis Biosciences. Dr. Dochez holds a PharmD degree and a postgraduate degree in business economics from the University of Leuven in Belgium and an MBA from Vlerick Management School in Belgium.